503A Price Audit Verified: Semaglutide $49/mo · Tirzepatide $99/mo ($0 Platform Membership · All Doses Locked) Claim $49 Rate →
Losing Weight RX Open-Data Desk
Record LWR-ST-02 · West Region CERN/Zenodo DOI: 10.5281/zenodo.24139340 View Full 51-Jurisdiction Dataset →

Alaska (AK) GLP-1 Telehealth Access, Medicaid Coverage & Clinic Cost Audit (2026)

Empirical regulatory and out-of-pocket pricing benchmark for Alaska residents evaluating Semaglutide and Tirzepatide in 2026. In-person Alaska weight loss clinics average $525/mo (Semaglutide) and $750/mo (Tirzepatide), compared to verified flat-rate telehealth programs at $49/mo and $99/mo across all dosage tiers.

AK Local Med-Spa Median
$525/mo Sema
$750/mo local Tirzepatide median
Annual Flat-Rate Savings
$5,712/yr
$7,812/yr saved on Tirzepatide ($99/mo flat)
Commercial PA Denial Rate
54.2%
Adult obesity prevalence: 35.4%
AK Access Equity Score
76/100
3-day cold-chain pharmacy transit

2026 Alaska Telehealth & Coverage Matrix

Regulatory / Economic Dimension Alaska (AK) Verified Status Patient Impact
Initial Telehealth Exam Rule Asynchronous Clinical Questionnaire Permitted Eligible patients can complete intake online at any hour for clinician review.
Adult Medicaid Obesity GLP-1 Coverage Excluded for Adult Obesity Only Cash-pay flat-rate telehealth provides immediate non-insurance access.
State Employee Health Plan GLP-1 Active Benefit Pathway Subject to plan-specific utilization management.
503A Sterile Pharmacy Licensing Tier Standard NABP Verified Non-Resident Pharmacy Reciprocity Cold-chain express delivery in ~3 business days statewide.
Semaglutide 12-Month Out-of-Pocket Local Clinic: $6,300/yr vs. Online Flat: $588/yr Saves $5,712/year ($0 monthly membership fee).
Tirzepatide 12-Month Out-of-Pocket Local Clinic: $9,000/yr vs. Online Flat: $1,188/yr Saves $7,812/year across 2.5 mg–15 mg tiers.

Primary Data Citation: Losing Weight RX Pharmacoeconomics & Consumer Audit Desk (2026). U.S. 50-State + D.C. Telehealth GLP-1 Prescribing Modality, Medicaid Coverage & Access Equity Matrix. DOI: 10.5281/zenodo.24139340 · State Reference: KFF AK State Health Facts.

Audited Metro Weight Loss Markets in Alaska (1 City)

Compare bricks-and-mortar bariatric clinic consultation fees and med-spa vial markups in Alaska's major metropolitan areas against flat-rate national telehealth delivery:

Anchorage, AK Clinic Cost Audit →

Interactive Alaska GLP-1 Household Savings Estimator

Select your medication and treatment horizon to compare Alaska local clinic pricing against flat-rate online delivery:

Estimated AK Savings
$5,712
Local: $6,300 vs Flat Online: $588

Frequently Asked Questions — Alaska (AK)

Does Alaska Medicaid cover GLP-1 medications for adult weight loss in 2026?

No. According to our November 2026 51-jurisdiction audit (DOI 10.5281/zenodo.24139340), Alaska (AK) Medicaid excludes adult anti-obesity GLP-1 coverage outside Type 2 diabetes or narrow cardiovascular indications. Coupled with an estimated 54.2% initial prior-authorization denial rate on commercial plans, many Alaska residents choose transparent flat-rate cash telehealth ($49/mo Semaglutide · $99/mo Tirzepatide, $0 membership fee).

Is an online questionnaire allowed for GLP-1 telehealth prescriptions in Alaska?

Yes. Alaska telehealth regulations permit asynchronous clinical questionnaire permitted when reviewed by a Alaska-licensed clinician who determines clinical eligibility, contraindications, and appropriate starting titration.

How much do local weight loss clinics in Alaska charge compared to online flat-rate care?

Across Alaska, local in-person med-spas and cash bariatric clinics charge a median of $525/month for compounded Semaglutide and $750/month for compounded Tirzepatide. Switching to verified flat-rate online care ($49/mo Semaglutide, $99/mo Tirzepatide across all doses) saves Alaska households an estimated $5,712/year on Semaglutide or $7,812/year on Tirzepatide.

Insurance PA Denial vs. Cash-Pay Calculator → 52-Week Dose-Titration Cost Calculator → Read Full 50-State Empirical Study → Compare Online Providers →

Clinical & Regulatory References

The clinical efficacy, safety, and Alaska telehealth regulatory information in Alaska (AK) GLP-1 Telehealth Access, Medicaid Coverage & Clinic Cost Audit (2026) is supported by the following peer-reviewed studies and authoritative .gov / .edu sources:

  1. Alaska Department of Health. (2025). Public health, chronic disease, and clinical telehealth resources. https://health.alaska.gov/
  2. Kim, N., Wang, J., Burudpakdee, C., Song, Y., Ramasamy, A., Xie, Y., Sun, R., Kumar, N., Wu, E. Q., & Sullivan, S. D. (2022). Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States. Journal of managed care & specialty pharmacy, 28(7), 740-752. https://doi.org/10.18553/jmcp.2022.28.7.740
  3. Liu, L., Cui, J., Neidecker, M. V., & Nahata, M. C. (2025). Tirzepatide vs semaglutide and liraglutide for weight loss in patients with overweight or obesity without diabetes: A short-term cost-effectiveness analysis in the United States. Journal of managed care & specialty pharmacy, 31(5), 441-450. https://doi.org/10.18553/jmcp.2025.31.5.441
  4. National Institute of Diabetes and Digestive and Kidney Diseases. (2023). Prescription medications to treat overweight and obesity. https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity
  5. UCLA Health. (2024). Semaglutide for weight loss: What you need to know. https://www.uclahealth.org/news/article/semaglutide-weight-loss-what-you-need-know
  6. Wang, S., Fan, D., Yao, Q., & Sun, X. (2025). The cost-utility and budget impact analyses of Tirzepatide versus once-weekly Semaglutide as add-on therapy to metformin in patients with type 2 diabetes mellitus in China. Diabetes, obesity & metabolism, 27(9), 5269-5279. https://doi.org/10.1111/dom.16580